-
EP3582804
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3582804
| EP3582804 - PHARMACEUTICAL COMBINATIONS FOR TREATING CANCER [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 08.12.2023 Database last updated on 14.11.2024 | |
| Former | Examination is in progress Status updated on 03.02.2023 | ||
| Former | Request for examination was made Status updated on 22.11.2019 | ||
| Former | The international publication has been made Status updated on 25.08.2018 | ||
| Former | unknown Status updated on 23.03.2018 | Most recent event Tooltip | 08.12.2023 | Application deemed to be withdrawn | published on 10.01.2024 [2024/02] | Applicant(s) | For all designated states Polyphor AG Hegenheimermattweg 125 4123 Allschwil / CH | [2019/52] | Inventor(s) | 01 /
BAUER, Michael Konrad-Adenauer-Strasse 32 79540 Lörrach / DE | 02 /
HOOFTMAN, Leon Gempenweg 16 4414 Arlesheim / CH | 03 /
ROMAGNOLI, Barbara Waldeckweg 24 CH-4102 Binningen / CH | [2019/52] | Application number, filing date | 18709923.9 | 20.02.2018 | [2019/52] | WO2018EP25042 | Priority number, date | EP20170020059 | 20.02.2017 Original published format: EP 17020059 | [2019/52] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2018149552 | Date: | 23.08.2018 | Language: | EN | [2018/34] | Type: | A1 Application with search report | No.: | EP3582804 | Date: | 25.12.2019 | Language: | EN | The application published by WIPO in one of the EPO official languages on 23.08.2018 takes the place of the publication of the European patent application. | [2019/52] | Search report(s) | International search report - published on: | EP | 23.08.2018 | Classification | IPC: | A61K39/00, A61K31/357, A61P35/00 | [2019/52] | CPC: |
A61K31/357 (EP,EA,IL,KR,US);
A61K38/12 (KR,US);
A61K38/10 (KR);
A61K9/0019 (US);
A61P35/00 (EP,EA,KR,US);
A61K2300/00 (IL,KR)
| C-Set: |
A61K31/357, A61K2300/00 (EP)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2019/52] | Extension states | BA | 19.09.2019 | ME | 19.09.2019 | Validation states | MA | 19.09.2019 | TN | 19.09.2019 | Title | German: | PHARMAZEUTISCHE KOMBINATIONEN ZUR BEHANDLUNG VON KREBS | [2019/52] | English: | PHARMACEUTICAL COMBINATIONS FOR TREATING CANCER | [2019/52] | French: | COMBINAISONS PHARMACEUTIQUES POUR TRAITER LE CANCER | [2019/52] | Entry into regional phase | 19.09.2019 | National basic fee paid | 19.09.2019 | Designation fee(s) paid | 19.09.2019 | Examination fee paid | Examination procedure | 19.09.2019 | Examination requested [2019/52] | 19.09.2019 | Date on which the examining division has become responsible | 20.04.2020 | Amendment by applicant (claims and/or description) | 07.02.2023 | Despatch of a communication from the examining division (Time limit: M06) | 18.08.2023 | Application deemed to be withdrawn, date of legal effect [2024/02] | 07.09.2023 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2024/02] | Fees paid | Renewal fee | 26.02.2020 | Renewal fee patent year 03 | 26.02.2021 | Renewal fee patent year 04 | 25.02.2022 | Renewal fee patent year 05 | 07.03.2023 | Renewal fee patent year 06 | Penalty fee | Additional fee for renewal fee | 28.02.2023 | 06 M06 Fee paid on 31.08.2023 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [XYI] - Simon Sonia Pernas, "Dose escalation of POL6326 in combination with eribulin in HER2-negative relapsed metastatic breast cancer (mBCa) patients (pts).: Journal of Clinical Oncology: Vol 34, No 15_suppl", Journal of Clinical Oncology, doi:10.1200/JCO.2016.34.15_suppl.2548, (20160520), pages 2548 - 2548, URL: http://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.2548, (20180423), XP055469396 [X] 1-13,15,16 * the whole document * [Y] 1-16 [I] 1-16 DOI: http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.2548 | [Y] - JINGYU XIANG ET AL, "Abstract 1114: Combination of a novel CXCR4 antagonist with chemotherapy reduces breast cancer bone metastatic tumor burden | Cancer Research", CANCER RESEARCH, (20141001), doi:10.1158/1538-7445.AM2014-1114, pages 114 - 114, XP055469478 [Y] 1-16 * the whole document * DOI: http://dx.doi.org/10.1158/1538-7445.AM2014-1114 | [Y] - J. XIANG ET AL, "CXCR4 Protein Epitope Mimetic Antagonist POL5551 Disrupts Metastasis and Enhances Chemotherapy Effect in Triple-Negative Breast Cancer", MOLECULAR CANCER THERAPEUTICS, US, (20150812), vol. 14, no. 11, doi:10.1158/1535-7163.MCT-15-0252, ISSN 1535-7163, pages 2473 - 2485, XP055469472 [Y] 1-16 * the whole document * DOI: http://dx.doi.org/10.1158/1535-7163.MCT-15-0252 | [T] - MARTA GIL-MARTIN ET AL, "Phase I study of the combination of balixafortide (CXCR4 inhibitor) and eribulin in HER2-negative metastatic breast cancer (MBC) patients (pts).: Journal of Clinical Oncology: Vol 35, No 15_suppl", JOURNAL OF CLINICAL ONCOLOGY, (20170520), vol. 35, no. 15, page 2555, XP055469882 [T] 1-16 * the whole document * | by applicant | - Eur J Ca, (20090000), vol. 45, pages 228 - 247 | - Clin Cancer Res, (20140000), vol. 20, no. 13, pages 3581 - 3588 | - SALGIA R; STILLE JR; WEAVER RW et al., "A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive-disease small cell lung cancer", Lung Cancer, (20170000), vol. 105, doi:doi:10.1016/j.lungcan.2016.12.020, pages 7 - 13, XP029930951 DOI: http://dx.doi.org/10.1016/j.lungcan.2016.12.020 | - CORTES J; O'SHAUGHNESSY J; LOESCH D et al., "Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study", Lancet, (20110000), vol. 377, no. 9769, doi:doi:10.1016/S0140-6736(11)60070-6, pages 914 - 923, XP055030961 DOI: http://dx.doi.org/10.1016/S0140-6736(11)60070-6 | - KAUFMAN PA; AWADA A; TWELVES C et al., "Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane", Journal of clinical oncology: official journal of the American Society of Clinical Oncology, (20150000), vol. 33, no. 6, pages 594 - 601 | - CORTES J; VAHDAT L; BLUM JL et al., "Phase II study of the halichondrin B anolog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane and capecitabine", Journal of clinical oncology: official journal of the American Society of Clinical Oncology, (20100000), vol. 28, no. 25, doi:doi:10.1200/JCO.2009.25.8467, pages 3922 - 3928, XP002678686 DOI: http://dx.doi.org/10.1200/JCO.2009.25.8467 | - VAHDAT LT; PRUITT B; FABIAN CJ et al., "Phase II study of eribulin mesylate, a halichondrin B anolog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane", Journal of clinical oncology: official journal of the American Society of Clinical Oncology, (20090000), vol. 27, no. 18, pages 2954 - 2961 | - SEYMOUR L; BOGAERTS J; PERRONE A et al., "iRECIST: guidelines for response criteria for use in trials testing immunotherapeut", Lancet Oncology, (20170000), vol. 18, no. 3, pages e143 - e152 |